Table 1.
Patient Characteristics
| Characteristic | No. | % |
|---|---|---|
| Eligible patients | 35 | |
| Age, years | ||
| Median | 64.5 | |
| Range | 32-79 | |
| Sex | ||
| Male | 23 | |
| Female | 12 | |
| Karnofsky score | ||
| Median | 90 | |
| Range | 70-100 | |
| Ann Arbor clinical stage | ||
| I | 1 | |
| II | 6 | |
| III | 13 | |
| IV | 15 | |
| LDH level | ||
| Median | 486 | |
| Range | 235-890 | |
| LDH elevated | 10 | 29 |
| FLIPI | ||
| I | 2 | |
| II | 5 | |
| III | 4 | |
| IV | 6 | |
| Median | 3 | |
| Marrow involvement | 12 | 34 |
| Histological subtype | ||
| Follicular | ||
| Total | 17 | |
| I | 5 | |
| II | 6 | |
| III | 6 | |
| Mantle cell | 9 | |
| Marginal zone | 9 | |
| Prior therapies | ||
| Autologous transplant | 8 | |
| Radioimmunotherapy | 3 | |
| Rituximab | 34 | |
| No. of prior chemotherapy regimens | ||
| Median | 2 | |
| Range | 0-4* | |
Abbreviations: LDH, lactate dehydrogenase; FLIPI, Follicular Lymphoma International Prognostic Index (for follicular lymphoma patients only).
*
Two patients received prior rituximab monotherapy alone.